# EDGAR Filing Document

**Accession Number:** 0001618835
**File Stem:** 0001493152-25-018454
**Filing Date:** 2025-10
**Character Count:** 12784
**Document Hash:** 8dc34b0c47fb7108002df1126fd5ca5c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-018454.hdr.sgml**: 20251017

**ACCESSION NUMBER**: 0001493152-25-018454

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251013

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251017

**DATE AS OF CHANGE**: 20251017

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evofem Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001618835
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 208527075
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36754
- **FILM NUMBER:** 251400850

**BUSINESS ADDRESS:**
- **STREET 1:** 12400 HIGH BLUFF DRIVE
- **STREET 2:** SUITE 600
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 550-1900

**MAIL ADDRESS:**
- **STREET 1:** 12400 HIGH BLUFF DRIVE
- **STREET 2:** SUITE 600
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neothetics, Inc.
- **DATE OF NAME CHANGE:** 20140905

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 13, 2025

**EVOFEM BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36754** | **20-8527075** |
| (State or other jurisdiction | (Commission | (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |

---

**7770 Regents Road, Suite 113-618**

**San Diego, California 92122**

(Address of principal executive offices)

**(858) 550-1900**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement**

***Amendment to Securities Purchase Agreement***

On October 13, 2025 (the "Effective Date"), Evofem Biosciences, Inc. (the "Company"), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, "Adjuvant") entered into a third amendment (the "Third Amendment") to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the "Notes").

The Third Amendment amends certain provisions within the Securities Purchase Agreement including updating the date that the Notes will be payable in full to the earlier of (a) six months after the Effective Date, (b) at the election of Adjuvant, the date of a consummation of a Change of Control (as defined in the Securities Purchase Agreement), and (c) the date of any acceleration of the Notes in accordance with Section 8 (the "Maturity Date", as per the Securities Purchase Agreement). The Notes may not be prepaid prior to the date that is six months after the Effective Date without prior written consent of Adjuvant.

**Item 9.01.** **Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Third Amendment to Securities Purchase Agreement dated as of October 13, 2025](ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **EVOFEM BIOSCIENCES, INC.** | **EVOFEM BIOSCIENCES, INC.** |
| Dated: October 17, 2025 | By: | */s/ Saundra Pelletier* |
|  |  | Saundra Pelletier |
|  |  | Chief Executive Officer |

---

## Exhibit 10.1

**<u>Exhibit 10.1</u>**

**<u>THIRD AMENDMENT TO SECURITIES PURCHASE AGREEMENT</u>**

This Third Amendment to Securities Purchase Agreement (this "<u>Third Amendment</u>") is entered into as of October 13, 2025 (the "<u>Third Amendment Effective Date</u>") by and among Evofem Biosciences, Inc., a Delaware corporation (the "<u>Company</u>"), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (the "<u>Purchasers</u>").

**RECITALS**

WHEREAS, the Company and the Purchasers are party to that certain Securities Purchase Agreement, dated as of October 14, 2020, as amended by that First Amendment to Securities Purchase Agreement, dated as of April 4, 2022, and by that Second Amendment to Securities Purchase Agreement, dated as of September 15, 2022 (as amended, the "<u>Purchase Agreement</u>"), pursuant to which the Purchasers purchased certain convertible promissory notes (the "<u>Notes</u>"; together with the Purchase Agreement, the "<u>Transaction Documents</u>") of the Company;

WHEREAS, pursuant to Section 10.8 of the Purchase Agreement, any term of the Purchase Agreement or the Notes may be amended only with the written consent of the Company and the Purchasers holding a majority of the outstanding balance, in the aggregate, of all Notes issued pursuant to the Purchase Agreement (the "<u>Requisite Purchasers</u>");

WHEREAS, the undersigned Purchasers constitute the Requisite Purchasers; and

WHEREAS, the Company and the Purchasers wish to amend the Purchase Agreement to address the provisions set forth herein effective as of the Third Amendment Effective Date.

NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

**AGREEMENT**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Definitions; References; Continuation of Purchase Agreement</u>. Unless otherwise specified herein, each capitalized term used herein that is defined in the Purchase Agreement shall have the meaning assigned to such term in the Purchase Agreement. Each reference to "hereof," "hereto," "hereunder," "herein" and "hereby" and each other similar reference, and each reference to "this Agreement", the "Securities Purchase Agreement" and each other similar reference, contained in the Purchase Agreement and any other Transaction Document shall from and after the date hereof refer to the Purchase Agreement as amended hereby. Except as amended or waived hereby, all terms and provisions of the Purchase Agreement and the Notes shall continue unmodified and remain in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Amendment to the Purchase Agreement</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <u>Amendment to Section 3.1 of the Purchase Agreement</u>. Effective as of the Third Amendment Effective Date, Section 3.1 of the Purchase Agreement is hereby deleted in its entirety and replaced with the following:

<u>Term</u>. The Notes and all accrued and unpaid interest thereon and any and all other sums payable to the Purchasers hereunder shall be due and payable in full on the earliest to occur of: (a) the date that is six months after the Third Amendment Effective Date, (b) at the election of the Purchasers, the date of the consummation of a Change of Control, and (c) the date of any acceleration of the Notes in accordance with Section 8 (the "<u>Maturity Date</u>"). Subject to Section 3.3, the Notes may not be prepaid prior to the date that is six months after the Third Amendment Effective Date without the prior written consent of the Purchasers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>Governing Law</u>. This Third Amendment shall be governed in all respects by and construed in accordance with the laws of the State of New York without regard to provisions regarding choice of laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <u>Continued Validity of Transaction Documents</u>. Unless otherwise modified or supplemented by the terms of this Third Amendment, all terms and conditions of the Transaction Documents shall continue in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <u>Titles and Subtitles</u>. The titles of the sections and clauses of this Third Amendment are for convenience of reference only and are not to be considered in construing this Third Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <u>Counterparts</u>. This Third Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. Delivery by facsimile or e-mail of an executed counterpart of a signature page shall be effective as delivery of an original executed counterpart.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 <u>Severability</u>. Should any provision of this Third Amendment be determined to be illegal or unenforceable, such determination shall not affect the remaining provisions of this Third Amendment.

[*Signature page follows.*]

**IN WITNESS WHEREOF**, the parties have executed this Third Amendment to Securities Purchase Agreement to be effective as of the date first above written.

---

| | |
|:---|:---|
| EVOFEM BIOSCIENCES, INC. | EVOFEM BIOSCIENCES, INC. |
| By: | /s/ Saundra Pelletier |
| Name: | Saundra Pelletier |
| Title: | Chief Executive Officer |

---

Address:

12400 High Bluff Drive, Suite 600

San Diego, CA 92130

Email:

*Signature Page to Third Amendment to Securities Purchase Agreement*

---

| | |
|:---|:---|
| ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. |
| as a Purchaser | as a Purchaser |
| By: | Adjuvant Capital GP, L.P., its General Partner |
| By: | Adjuvant Capital Management, LLC, its General Partner |

---

---

| | |
|:---|:---|
| By: | /s/ Kabeer Aziz |
| Name: | Kabeer Aziz |
| Title: | Vice President & Secretary |

---

Address:

500 Fifth Avenue, Suite 4000

New York, NY 10110

Email:

*Signature Page to Third Amendment to Securities Purchase Agreement*

---

| | |
|:---|:---|
| ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND DE, L.P. | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND DE, L.P. |
| as a Purchaser | as a Purchaser |
| By: | Adjuvant Capital GP, L.P., its General Partner |
| By: | Adjuvant Capital Management, LLC, its General Partner |

---

---

| | |
|:---|:---|
| By: | /s/ Kabeer Aziz |
| Name: | Kabeer Aziz |
| Title: | Vice President & Secretary |

---

Address:

500 Fifth Avenue, Suite 4000

New York, NY 10110

Email:

*Signature Page to Third Amendment to Securities Purchase Agreement*